Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor

Internal Medicine Journal

Volumn 32, Issue 1-2, 2002, Pages 50-51

  Virik, Kiran ^a,c   Lynch, K P ^b   Harper, P ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b British Biotech Pharmaceuticals Ltd   (United Kingdom)

^c BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MARIMASTAT; METALLOPROTEINASE INHIBITOR;

ARTICLE; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; ESOPHAGUS CARCINOMA; EXTRACELLULAR MATRIX; FASCIITIS; GASTROESOPHAGEAL CANCER; GENE OVEREXPRESSION; HUMAN; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCLERODERMA; STOMACH CARCINOMA;

ADENOCARCINOMA; AGED; ENZYME INHIBITORS; ESOPHAGEAL NEOPLASMS; FASCIITIS; HUMANS; HYDROXAMIC ACIDS; MALE; METALLOENDOPEPTIDASES; PARANEOPLASTIC SYNDROMES; STOMACH NEOPLASMS;

EID: 0036968798     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-5994.2002.00153.x     Document Type: Article

References (8)

1. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases. Biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135-49.
2. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-22.
3. Saxman SB, Seitz D. Breast cancer associated with palmar fasciitis and arthritis. J Clin Oncol 1997; 15: 3515-16.
4. Ku A, Lachmann E, Tunkel R et al. Upper limb reflex sympathetic dystrophy associated with occult malignancy. Arch Phys Med Rehabil 1996; 77: 726-8.
5. Pfinsgraff J, Buckingham RB, Killian PJ, Keister SR, Brereton WF, Weinblatt ME et al. Palmar fasciitis and arthritis with malignant neoplasms: a paraneoplastic syndrome. Semin Arthritis Rheum 1986; 16: 118-25.
6. Tierney GM, Griffin NR, Stuart RC, Kasem H, Lynch KP, Lury JT et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur J Cancer 1999; 35: 563-8.
7. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93: 178-93.
8. Sollberg S, Krieg T. New aspects in scleroderma research. Int Arch Allergy Immunol 1996; 111: 330-6.